Jpmorgan Chase & CO Kazia Therapeutics LTD Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 37,826 shares of KZIA stock, worth $55,604. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,826
Previous 3
1260766.67%
Holding current value
$55,604
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding KZIA
# of Institutions
17Shares Held
2.09MCall Options Held
93.2KPut Options Held
0-
Mai Capital Management1.36MShares$2 Million0.01% of portfolio
-
Ubs Group Ag249KShares$366,6940.0% of portfolio
-
Morgan Stanley New York, NY220KShares$323,7830.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il60.5KShares$88,8990.0% of portfolio
-
Jane Street Group, LLC New York, NY46.1KShares$67,7810.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $22.2M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...